{"id":"arct-2303","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL578062","moleculeType":"Small molecule","molecularWeight":"383.95"},"_fixedAt":"2026-03-30T13:02:44.563177","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ARCT-2303 uses Arcturus' proprietary self-amplifying RNA technology to deliver genetic instructions for tumor antigens, triggering both innate and adaptive immune responses. The saRNA platform allows for lower doses while maintaining immunogenicity, and the vaccine is designed to work in combination with checkpoint inhibitors to enhance anti-tumor immunity.","oneSentence":"ARCT-2303 is a self-amplifying RNA (saRNA) vaccine that encodes tumor-associated antigens to stimulate CD8+ T-cell immune responses against cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:14.813Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pancreatic cancer (in combination with checkpoint inhibitor)"},{"name":"Non-small cell lung cancer (in combination with checkpoint inhibitor)"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT06279871","phase":"PHASE3","title":"Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-03-27","conditions":"COVID-19","enrollment":1514}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2025 Sep","pmid":"40896462","title":"Immunogenicity and safety of self-amplifying mRNA COVID-19 vaccine (ARCT-2303), with or without co-administration of seasonal inactivated influenza vaccine in adults: a phase 3, randomised, controlled, observer-blind, multicentre study.","journal":"EClinicalMedicine"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ARCT-2303","genericName":"ARCT-2303","companyName":"Arcturus Therapeutics, Inc.","companyId":"arcturus-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"ARCT-2303 is a self-amplifying RNA (saRNA) vaccine that encodes tumor-associated antigens to stimulate CD8+ T-cell immune responses against cancer cells. Used for Pancreatic cancer (in combination with checkpoint inhibitor), Non-small cell lung cancer (in combination with checkpoint inhibitor).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}